Can TECNIS PureSee help Johnson & Johnson win the next phase of premium cataract surgery?
Johnson & Johnson’s TECNIS PureSee data could reshape premium cataract surgery. Read what the ASCRS 2026 findings may change next.
Can ZEISS turn ophthalmology workflow software into the next battleground in cataract care?
ZEISS unveiled new AI, cataract planning, and cloud workflow tools at ASCRS 2026. Read what this means for ophthalmology practices.
Why Bausch + Lomb’s ASCRS 2026 data slate matters for premium IOL competition and dry eye care
Find out why Bausch + Lomb’s ASCRS 2026 data package could reshape competition in cataract surgery, dry eye care, and ophthalmology platforms.
Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?
Alcon launched Clareon TruPlus at ASCRS 2026. Read why the new enhanced monofocal IOL could reshape cataract lens choice.
Johnson & Johnson’s TECNIS PureSee approval highlights the evolving battle between EDOF and multifocal cataract lenses
Johnson & Johnson wins FDA approval for TECNIS PureSee IOL. Discover what this extended depth of focus cataract lens means for surgeons and patients.
NMPA greenlights ZEISS ARTEVO 750 and 850, boosting China’s surgical visualization tech
ZEISS receives NMPA approval in China for ARTEVO 750 and 850 ophthalmic microscopes. Find out how these devices are shaping the future of eye surgery.